New oral drug shows promise in early arthritis trial

NCT ID NCT06800157

Completed Disease control Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new oral medication called LW402 in 72 adults with moderate to severe rheumatoid arthritis who were already taking methotrexate. Participants received either LW402 or a placebo for 12 weeks to see if the drug could reduce joint swelling and pain. The goal was to find the right dose and check for safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LW402 tablets
What this could lead to: If successful, this could point toward a new oral treatment option for rheumatoid arthritis, helping to control disease activity when used with methotrexate.
What could go wrong: This is an early Phase 2a study with only 72 participants, so results may not apply to everyone. The drug may not show significant benefit over placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS, RHEUMATOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRITIS, RHEUMATOID

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.